CJC-1295 & Ipamorelin

How CJC-1295 Works as a GHRH Analogue

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

CJC-1295 is an agonist at the growth hormone-releasing hormone receptor on pituitary somatotrophs. It is based on the active GRF(1-29) fragment of native GHRH (twenty-nine residues ending in argininamide) with four substitutions that resist enzymatic degradation, chiefly by blocking the DPP-4 cleavage site at the N-terminus.

Key facts

Receptor
GHRH receptor (GHRHR)
Location
Pituitary somatotrophs
Basis
GRF(1-29), the active GHRH fragment
Substitutions
D-Ala2, Gln8, Ala15, Leu27
Native GHRH half-life
Minutes
Normal signalling
Pulsatile

What GHRH normally does

Growth hormone-releasing hormone is produced in the hypothalamus and travels through the hypophyseal portal circulation to the anterior pituitary, where it acts on somatotrophs to stimulate GH synthesis and release. Its release is pulsatile, and the resulting GH secretion is pulsatile too, a pattern that appears to matter for downstream effects.

Why only the first 29 residues

Native GHRH is 44 residues but its receptor-activating capacity resides in the N-terminal region. GRF(1-29) retains full agonist activity, which is why sermorelin (native GRF(1-29)) was developed as a therapeutic and why CJC-1295 starts from that fragment rather than the whole hormone.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £42.99

What each substitution addresses

D-alanine at position 2 is the critical one: DPP-4 cleaves GHRH after residue 2, and a D-amino acid is not a substrate. Gln8, Ala15 and Leu27 address further degradation-prone points. Together they take the peptide from a half-life of minutes to roughly thirty, without altering the receptor interaction.

The pulsatility question the DAC form raises

Physiological GHRH arrives in pulses. A covalently albumin-bound analogue produces continuous receptor exposure instead, which is a different stimulus. Ionescu and Frohman addressed this in 2006, reporting that pulsatile GH secretion persists during continuous stimulation. The pituitary appears to impose its own rhythm rather than simply following the input.

Why the receptor is a good target

Acting upstream at GHRH rather than administering GH directly means the pituitary retains its own regulatory feedback. That is a meaningfully different intervention from exogenous GH, and it is the general rationale for secretagogue approaches, whichever receptor they use.

Frequently asked questions

Where does CJC-1295 act?

At the GHRH receptor on pituitary somatotrophs, the same receptor native GHRH uses.

Why GRF(1-29) rather than full GHRH?

Receptor-activating capacity resides in the N-terminal region; the 29-residue fragment retains full agonist activity.

Does continuous stimulation flatten GH pulses?

Ionescu and Frohman reported pulsatile GH secretion persisting during continuous stimulation, with the pituitary imposing its own rhythm.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More CJC-1295 & Ipamorelin articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.